Frontiers of Science: Omega-3 polyunsaturated fatty acids and inflammatory processes: from the membrane to the nucleus and from the lab bench to the bedside
Prof. Philip Calder, University of Southampton, UK
Omega-3 polyunsaturated fatty acids and inflammatory processes: from the membrane to the nucleus and from the lab bench to the bedside
Host: Kirsi Laitinen (email@example.com)
Professor Philip Calder is Head of Human Development & Health and Professor of Nutritional Immunology within Medicine at the University of Southampton, Southampton, UK. He has broad research interests in nutritional modulation of immunity, inflammation and cardiometabolic disease risk. Much of his work has been devoted to exploring the metabolism and functionality of fatty acids with an emphasis on the roles of omega-3 fatty acids. He has over 500 scientific publications and he is listed as a Highly Cited Researcher. He has been awarded several national and international research awards and he has served on many committees of professional societies and Editorial Boards of journals in the nutrition, clinical science and lipidology fields. He is a Fellow of the Royal Society for Biology, the Association for Nutrition, the Higher Education Academy and International Society for the Study of Fatty Acids and Lipids.
For further details, please see: https://www.southampton.ac.uk/medicine/about/staff/pcc.page
In his presentation prof Calder will address the role of inflammation in common human diseases, the mechanisms by which omega-3 fatty acids reduce inflammation, and the use of omega-3 fatty acids in specific patient groups.
Ostermann, A.I., West, A.L., Schoenfeld, K., Browning, L.M., Walker, C.G., Jebb, S.A., Calder, P.C. and Schebb, N.H., Plasma oxylipins respond in a linear dose-response manner with increased intake of EPA and DHA: results from a randomized controlled trial in healthy humans. American Journal of Clinical Nutrition, 109, 2019, 1251-1263.
West, A.L., Kindberg, G.M., Hustvedt, S.O., and Calder, P.C., A novel self-micro-emulsifying delivery system enhances enrichment of eicosapentaenoic acid and docosahexaenoic acid after single and repeated dosing in healthy adults in a randomized trial. Journal of Nutrition, 148, 2018, 1704-1715.
Calder, P.C., Laviano, A., Lonnqvist, F., Muscaritoli, M., Öhlander, M. and Schols, A., Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial. Journal of Cachexia Sarcopenia and Muscle, 9, 2018, 28-40.
Innes, J.K. and Calder, P.C., The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiometabolic risk factors: A systematic review. International Journal of Molecular Sciences, 19, 2018, 532.
Jeffery, L., Fisk, H.L., Calder, P.C., Filer, A., Raza, K., Buckley, C.D., McInnes, I., Taylor, P.C. and Fisher, B.A., Plasma levels of eicosapentaenoic acid are associated with anti-TNF responsiveness in rheumatoid arthritis and inhibit the etanercept-driven rise in Th17 cell differentiation in vitro. Journal of Rheumatology, 44, 2017, 748-756.
West, A.L., Burdge, G.C. and Calder, P.C., Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial. British Journal of Nutrition, 116, 2016, 788-797.
Del Bas, J.M., Caimari, A., Rodriguez-Naranjo, M.I., Childs, C.E., Paras Chavez, C., West, A.L., Miles, E.A., Arola, L. and Calder, P.C., Impairment of lysophospholipid metabolism in obesity: altered plasma profile and desensitization to the modulatory properties of n-3 polyunsaturated fatty acids in a randomized controlled trial. American Journal of Clinical Nutrition, 104, 2016, 266-279.